Skip to content

Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease

Serum Interleukin 6 in Chronic Obstructive Pulmonary Disease Patients and Its Relation to Severity and Acute Exacerbation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05214508
Enrollment
90
Registered
2022-01-28
Start date
2020-03-01
Completion date
2020-11-30
Last updated
2022-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstr Lung Disease

Brief summary

The aim of this study is to estimate level of IL 6 in COPD patients and its relation to COPD severity and acute exacerbation.

Detailed description

1. A detailed clinical history was be carried out for every patient. In the clinical history, duration of COPD with a history of exacerbation and treatment will be elicited. History of the presence of risk factors such as smoking, exposure to fumes (biomass), and the presence of any other chronic disease were be inquired. 2. Thereafter, the detailed physical examination also had been carried out. 3. Pulmonary function test was performed by master screen NO : 781040 (care fusion) Measurements were obtained for FVC,FEV1,Ratio between them, PEF,FEF25%,FEF50% ,and FEF75% (The readings for FEV1 and Ratio were the ones included in the statistical analysis as indices for obstructive pattern of respiration). 4. Labs including Complete blood count, urea, and serum creatinine ,ESR was done for all patients 5. Exercise capacity by six minutes' walk test. 6. Dyspnea score by MMRC score. 7. Health state assessment by CAT score 3- 8- Determination of IL 6 serum levels. by sandwich enzyme-linked immunosorbent assay (ELISA). The detection range (0.2 ng/L- 8ng/L)

Interventions

DIAGNOSTIC_TESTinterleukin 6

assessment of serum IL-6 by ELISA

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

1. All patients aged \>40 years and \<80 years, of both gender 2. Diagnosed to have COPD according to GOLD 2019 by spirometry 3. Given the consent for participation in the study

Exclusion criteria

1- Any patient with systemic inflammation as 1. Bronchial asthma, 2. rheumatoid arthritis.

Design outcomes

Primary

MeasureTime frameDescription
measure level of IL-69 monthesusing ELISA

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026